Innovating with blood-based 'liquid biopsies' for colorectal cancer, offering higher patient compliance and leveraging AI for multi-cancer early detection.

A moderately bearish signal, as an insider made a large $17 million sale, his first in a very long time, after the stock ran up 100%. The signal is tempered by his mixed (50%) historical track record.